This TNFR2 agonist mAb enhanced tumor infiltration and IFN-γ synthesis by CD8+ T cells in the CT26 tumor model, resulting in tumor growth inhibition and prolonging survival by approximately 5–15 days (Figure 5). This evidence concerns the gene IFNG and neoplasm.